EUVIMEDEUVIMED entdecken
Crossref

Clinical outcomes of patients undergoing reoperation with solitary fibrous tumors/hemangiopericytomas and malignant progression of tumors

Long Chen, Runfeng Wang, JianQing He, Haiyang Wu, Yunze Zhang, Yang Wu, Tianzhi Zhao, Yan Qu, Yingxi Wu

Neurosurgical Review · 2024

DOI: 10.1007/s10143-024-02956-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurosurgical Review, 2024. Verfasst von Long Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Tangdu Hospital, Air Force Medical University, No.1 Xin Si Road, Xi'an, 710038, China. Hauptthemen laut MEDLINE: Reoperation, Hemangiopericytoma, Disease Progression, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: the Scientific Research Fund Project of Hebei Provincial Health and Family Planning Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: The purpose of this study was to analyze the clinical outcomes and malignant progression of tumors in patients who underwent reoperation for recurrent solitary fibrous tumors (SFTs) and hemangiopericytomas (HPCs). METHODS: We identified 48 patients who underwent reoperation because of tumor recurrence at Tangdu Hospital between January 2010 and December 2021 and analyzed the clinical outcomes, namely, the rate of gross total resection (GTR), progression-free survival (PFS), overall survival (OS), malignant progression of tumors and radiotherapy. The survival curves for each group were plotted using the Kaplan‒Meier method and compared using log-rank tests. RESULTS: Of the 48 patients (25 men and 23 women, mean age 49.5 ± 14.3 years), 25 experienced a second recurrence or metastasis, 15 of whom underwent a third surgery, and the remaining 10 patients who did not undergo surgery ultimately died after tumor progression. The median time (95% CI) to tumor recurrence was 40.0 (32.3-47.7) months after reoperation, with 3-, 5- and 10-year PFS rates of 54.6%, 29.5% and 14.8%, respectively. The median (95% CI) survival time was 70.0 (46.6-93.4) months, with 3-, 5- and 10-year survival rates of 67.9%, 55.1% and 36.7%, respectively. Among the 48 patients who underwent reoperation, 27 (56.3%) achieved GTR, and 21 (43.8%) achieved STR. Twelve patients in the GTR group (12/27, 44.4%) received radiotherapy after surgery, and 18 patients in the STR group (18/21, 85.7%) received radiotherapy. Of the 48 recurrent SFTs, 24 were classified as WHO grade 1, 14 were classified as WHO grade 2, and 10 were classified as WHO grade 3 based on 2021 WHO classification after the primary operation. After reoperation, 9 tumors developed malignant progression, including 4 WHO grade 1 tumors progressing to WHO grade 2 tumors, 1 WHO grade 1 tumor progressing to a WHO grade 3 tumor and 4 WHO grade 2 tumors progressing to WHO grade 3 tumors. CONCLUSIONS: GTR after reoperation was associated with better PFS and OS compared to STR. However, the PFS after the third surgery was significantly shorter than that after the second surgery, and the rate of GTR also decreased. Malignant progression may occur after second or third tumor recurrence. Furthermore, compared with WHO grade 1 SFTs, WHO grade 2 and grade 3 SFTs significantly decreased PFS, but OS did not differ among the three groups. Radiotherapy did not prolong PFS or OS in patients who underwent reoperation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ReoperationHemangiopericytomaDisease ProgressionNeoplasm Recurrence, LocalSolitary Fibrous TumorsHumansMaleFemaleMiddle AgedAdultAgedTreatment OutcomeProgression-Free SurvivalRetrospective Studies

Stichwörter der Autor:innen

HemangiopericytomaMalignant progressionMetastasisOverall survivalProgression-free survivalRecurrenceSolitary fibrous tumorWHO grade classification

Autor:innen und Institutionen

  • Department of Neurosurgery, Tangdu Hospital, Air Force Medical University, No.1 Xin Si Road, Xi'an, 710038, China.
  • Department of Neurosurgery, The 904th Hospital of Joint Logistic Support Force, Wu xi, China.
  • Department of Neurosurgery, The second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
  • Department of Neurosurgery, Tangdu Hospital, Air Force Medical University, No.1 Xin Si Road, Xi'an, 710038, China. yanqu0123@fmmu.edu.cn.
  • Department of Neurosurgery, Tangdu Hospital, Air Force Medical University, No.1 Xin Si Road, Xi'an, 710038, China. 476620343@qq.com.

Förderung

  • the Scientific Research Fund Project of Hebei Provincial Health and Family Planning Commission

Zitieren

APA

Chen, L., Wang, R., He, J., Wu, H., Zhang, Y., Wu, Y., Zhao, T., Qu, Y., & Wu, Y. (2024). Clinical outcomes of patients undergoing reoperation with solitary fibrous tumors/hemangiopericytomas and malignant progression of tumors. Neurosurgical Review. https://doi.org/10.1007/s10143-024-02956-2

Vancouver

Chen L, Wang R, He J, Wu H, Zhang Y, Wu Y, et al. Clinical outcomes of patients undergoing reoperation with solitary fibrous tumors/hemangiopericytomas and malignant progression of tumors. Neurosurgical Review. 2024. doi:10.1007/s10143-024-02956-2

BibTeX
@article{Chen2024,
  author = {Chen, Long and Wang, Runfeng and He, JianQing and Wu, Haiyang and Zhang, Yunze and Wu, Yang and Zhao, Tianzhi and Qu, Yan and Wu, Yingxi},
  title = {Clinical outcomes of patients undergoing reoperation with solitary fibrous tumors/hemangiopericytomas and malignant progression of tumors},
  journal = {Neurosurgical Review},
  year = {2024},
  doi = {10.1007/s10143-024-02956-2}
}
Kostenlos starten →